Skip to main content
. 2018 Oct 22;18:1012. doi: 10.1186/s12885-018-4911-7

Fig. 2.

Fig. 2

Cumulative incidence of brain metastasis progression using competing risks regression analysis in patients treated with gefitinib or erlotinib. a All patients in this study. b Patients who had brain metastasis before EGFR-TKI administration. c Patients who had no brain metastasis before EGFR-TKI administration